» Articles » PMID: 36225536

Pulmonary Hypertension in Patients with Interstitial Lung Disease: a Tool for Early Detection

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2022 Oct 13
PMID 36225536
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists regarding which patients to screen for PH-ILD or the optimal method to do so. The aim of this study was to create a risk assessment tool that could reliably predict PH in ILD patients. We developed a PH-ILD Detection tool that incorporated history, exam, 6-min walk distance, diffusion capacity for carbon monoxide, chest imaging, and cardiac biomarkers to create an eight-component score. This tool was analyzed retrospectively in 154 ILD patients where each patient was given a score ranging from 0 to 12. The sensitivity (SN) and specificity (SP) of the PH-ILD Detection tool and an area-under-the-curve (AUC) were calculated. In this cohort, 74 patients (48.1%) had PH-ILD. A score of ≥6 on the PH-ILD Detection tool was associated with a diagnosis of PH-ILD (SN: 86.5%; SP: 86.3%; area-under-the-curve: 0.920,  < 0.001). The PH-ILD Detection tool provides high SN and SP for detecting PH in ILD patients. With confirmation in larger cohorts, this tool could improve the diagnosis of PH in ILD and may suggest further testing with right heart catheterization and earlier intervention with inhaled treprostinil and/or lung transplant evaluation.

Citing Articles

Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease.

Kim H, Chandel A, King C, Kim M, Shawabkeh M, Arunachalam A Lung. 2025; 203(1):27.

PMID: 39841267 PMC: 11754375. DOI: 10.1007/s00408-024-00783-2.


Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.

Nathan S, Stinchon Jr M, Atcheson S, Simone L, Nelson M J Manag Care Spec Pharm. 2025; 31(1-a Suppl):S2-S17.

PMID: 39745852 PMC: 11695281. DOI: 10.18553/jmcp.2025.31.1-a.s2.


Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.

PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.


Noninvasive diagnostic modalities and prediction models for detecting pulmonary hypertension associated with interstitial lung disease: a narrative review.

Arvanitaki A, Diller G, Gatzoulis M, McCabe C, Price L, Wort S Eur Respir Rev. 2024; 33(174).

PMID: 39384306 PMC: 11462299. DOI: 10.1183/16000617.0092-2024.


Scoping review of post-TB pulmonary vascular disease: Proceedings from the 2nd International Post-Tuberculosis Symposium.

Louw E, Van Heerden J, Kalla I, Maarman G, Nxumalo Z, Thienemann F Pulm Circ. 2024; 14(3):e12424.

PMID: 39268398 PMC: 11391472. DOI: 10.1002/pul2.12424.


References
1.
Mar P, Nwazue V, Black B, Biaggioni I, Diedrich A, Paranjape S . Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction. Chest. 2016; 149(5):1252-60. PMC: 4944774. DOI: 10.1016/j.chest.2015.11.015. View

2.
Nathan S, Barbera J, Gaine S, Harari S, Martinez F, Olschewski H . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2018; 53(1). PMC: 6351338. DOI: 10.1183/13993003.01914-2018. View

3.
Eaton T, Young P, Milne D, Wells A . Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005; 171(10):1150-7. DOI: 10.1164/rccm.200405-578OC. View

4.
Nathan S, Shlobin O, Ahmad S, Urbanek S, Barnett S . Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007; 131(3):657-663. DOI: 10.1378/chest.06-2485. View

5.
Nathan S, Shlobin O, Barnett S, Saggar R, Belperio J, Ross D . Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2008; 102(9):1305-10. PMC: 2649722. DOI: 10.1016/j.rmed.2008.03.022. View